Every material Form 8-K Cardiff Oncology, Inc. has filed with the SEC since August 11, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Cardiff Oncology said its Chief Medical Officer, Roger Sidhu, separated from the company on October 22, 2026, in a mutually agreed transition. The company appointed Dr. Leila Alland as interim Chief Medical Officer under a consulting agreement, and it also increased its authorized common stock to 300,000,000 shares. The filing does not include financial results or guidance.
Roger Sidhu separated from the company as Chief Medical Officer on October 22, 2026, in a mutually agreed transition.
Dr. Leila Alland's consulting agreement began October 23, 2026, and runs until April 22, 2027, or earlier if all services are completed.
Dr. Alland will be paid a monthly fee of $35,000 and will devote up to 50% of her professional time to the role.
Authorized common stock was increased to 300,000,000 shares, effective October 22, 2026.
Cardiff Oncology and Nerviano Medical Sciences agreed on September 14, 2026 to settle their pending litigation, with both parties dismissing the case with prejudice and exchanging mutual releases, and no monetary payment made between them. The companies also amended the 2017 license agreement for onvansertib, changing exclusivity, royalty, milestone, governance and assignment terms, which matters to shareholders because it reshapes the economics and conditions of the company's lead asset.
Settlement and Amendment dated September 14, 2026; the Amendment takes full effect when the case is dismissed with prejudice.
No monetary payment was made by either party to resolve the litigation, and neither party admitted liability.
Amendment adds an additional license fee on annual net sales of products practicing a valid Company patent claim, in lieu of the existing royalty.
If Cardiff assigns the license, including by merger or change of control, before Phase III data readout, it would owe Nerviano a percentage of transaction proceeds based on Phase III dosing timing.
Cardiff Oncology reported a second-quarter 2026 net loss of $9.2 million, or $0.14 per share, down from $13.9 million, or $0.21 per share, a year earlier, as research and development spending fell. Royalty revenue slipped to $104,000 from $121,000, and cash, cash equivalents and short-term investments were $34.5 million at June 30, 2026, before a $10 million registered direct offering completed after quarter end. The company says its cash resources fund operations into the third quarter of 2027, and it plans to start a Phase 3 trial in the first quarter of 2027 subject to securing additional financing.
Q2 2026 net loss was $9.2 million ($0.14 per share) versus $13.9 million ($0.21 per share) in Q2 2025.
Royalty revenue was $104,000 versus $121,000; total operating expenses were $9.7 million versus $14.9 million.
Cash, cash equivalents and short-term investments were $34.5 million at June 30, 2026, excluding the $10 million offering completed after quarter end.
Cash resources are expected to fund operations into the third quarter of 2027; Phase 3 start planned for Q1 2027, subject to additional financing.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Cardiff Oncology, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →